How to Recognize, Diagnose, and Treat Patients With BPDCN

Long-Term BPDCN Data Show Potential for Durable CRs and Transplant

During a live event, Taha Al-Juhaishi, MD, discussed long-term outcomes of treating blastic plasmacytoid dendritic cell neoplasm and how to navigate toxicities and transplant.

Targeted Therapy for BPDCN Provides Path to Allogeneic Transplant

During a live event, Taha Al-Juhaishi, MD, discussed his experience treating blastic plasmacytoid dendritic cell neoplasm and getting patients to allogeneic transplant.

Tagraxofusp Yields Deep Responses as Frontline BPDCN Therapy

During a live event, Gary J. Schiller, MD, explored the outcomes of the phase 1/2 trial of tagraxofusp-erzs in patients with blastic plasmacytoid dendritic cell neoplasm.

Unique Diagnostic Profile for BPDCN Warrants Focus on Hematopathology

During a live event, Gary J. Schiller, MD, reviewed the diagnostics and characteristics of blastic plasmacytoid dendritic cell neoplasm.

Optimizing Tagraxofusp in BPDCN with Early CPS Detection Strategies

Marlise R. Luskin, MD, MSCE, discusses the vigilant monitoring required for capillary leak syndrome with tagraxofusp in BPDCN.

Exploring Newer Treatment Options With Tagraxofusp in BPDCN

Marlise R. Luskin, MD, MSCE, discussed treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and challenging disease.

Tagraxofusp Shows Encouraging Response Rate in Patients With BPDCN

Marlise R. Luskin, MD, MSCE, discusses the trial of tagraxofusp in BPDCN, which showed high response rates and overall survival.

Desai and Participants Differentiate BPDCN From Other Diagnoses

During a Case-Based Roundtable® event, Pinkal Desai, MD, MPH, discusses the presentation of blastic plasmacytoid dendritic cell neoplasm vs other diseases in a patient case.

How to Handle CLS From Tagraxofusp and Maintain Treatment in BPDCN

During a Case-Based Roundtable® event, Thomas W. LeBlanc, MD, MA, MHS, discusses the adverse events, like capillary leak syndrome, that come with the use of tagraxofusp when treating patients with blastic plasmacytoid dendritic cell neoplasm in the second article of a 2-part series.

Why Physicians Recommend Tagraxofusp in BPDCN

During a Case-Based Roundtable® event, Thomas W. LeBlanc, MD, MA, MHS, discusses why he recommends tagraxofusp-exrs for patients with blastic plasmacytoid dendritic cell neoplasm in need of treatment in the first article of a 2-part series.

Interpreting Safety and Efficacy Data for Tagraxofusp in BPDCN

During a Targeted Oncology™ Case-Based Roundtable™ event, Uma Borate, MBBS, moderated discussion of physicians' familiarity with diagnosis and treatment of blastic plasmacytoid dendritic cell neoplasm. This is the second of 2 articles based on this event.

Diagnostic Approaches for Hematologic Malignancies With Skin Symptoms

During a Targeted Oncology™ Case-Based Roundtable™ event, Uma Borate, MBBS, asked physicians about their experiences with patients with hematological malignancies with skin manifestations, and how to diagnose and work up these patients. This is the first of 2 articles based on this event.

Lancet Reviews the Key Treatment Options for BPDCN

During a Targeted Oncology case-based roundtable event, Jeffrey E. Lancet, MD, discussed the data behind tagraxofusp in patients with blastic plasmacytoid dendritic cell neoplasm. This is the second of 2 articles based on this event.

Exploring the Background and Clinical Presentation of BPDCN

During a Targeted Oncology case-based roundtable event, Jeffrey E. Lancet, MD, discussed the clinical presentation of blastic plasmacytoid dendritic cell neoplasm and how it came to be recognized as a distinct rare hematologic malignancy. This is the first of 2 articles based on this event.

Multi-Stage Trial of Tagraxofusp Shows Frontline Efficacy in BPDCN

Andrew A. Lane, MD, PhD, discusses the study design of a phase 1/2 trial of tagraxofusp-erzs for patients with blastic plasmacytoid dendritic cell neoplasms.